BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 16172308)

  • 1. Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study.
    de Quatrebarbes J; Estève E; Bagot M; Bernard P; Beylot-Barry M; Delaunay M; D'Incan M; Souteyrand P; Vaillant L; Cordel N; Courville P; Joly P
    Arch Dermatol; 2005 Sep; 141(9):1117-20. PubMed ID: 16172308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of mycosis fungoides to topical chemotherapy with mechlorethamine.
    Ramsay DL; Parnes RE; Dubin N
    Arch Dermatol; 1984 Dec; 120(12):1585-90. PubMed ID: 6508330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.
    Kim YH; Jensen RA; Watanabe GL; Varghese A; Hoppe RT
    Arch Dermatol; 1996 Nov; 132(11):1309-13. PubMed ID: 8915308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma.
    Talpur R; Venkatarajan S; Duvic M
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):591-7. PubMed ID: 25068889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical nitrogen mustard in mycosis fungoides.
    Zachariae H
    Int J Clin Pharmacol Res; 1985; 5(3):193-8. PubMed ID: 4018954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.
    Lessin SR; Duvic M; Guitart J; Pandya AG; Strober BE; Olsen EA; Hull CM; Knobler EH; Rook AH; Kim EJ; Naylor MF; Adelson DM; Kimball AB; Wood GS; Sundram U; Wu H; Kim YH
    JAMA Dermatol; 2013 Jan; 149(1):25-32. PubMed ID: 23069814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.
    Duvic M; Sherman ML; Wood GS; Kuzel TM; Olsen E; Foss F; Laliberté RJ; Ryan JL; Zonno K; Rook AH
    J Am Acad Dermatol; 2006 Nov; 55(5):807-13. PubMed ID: 17052486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides.
    Demierre MF; Vachon L; Ho V; Sutton L; Cato A; Leyland-Jones B
    Arch Dermatol; 2003 May; 139(5):624-8. PubMed ID: 12756099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycosis fungoides plaque stage treated with topical nitrogen mustard with and without attempts at tolerance induction: report from the Scandinavian mycosis fungoides study group.
    Molin L; Thomsen K; Volden G
    Acta Derm Venereol; 1979; 59(1):64-8. PubMed ID: 84470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience.
    Kim YH; Martinez G; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Feb; 139(2):165-73. PubMed ID: 12588222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical nitrogen mustard in early mycosis fungoides. A 12-year experience.
    Zachariae H; Thestrup-Pedersen K; Søgaard H
    Acta Derm Venereol; 1985; 65(1):53-8. PubMed ID: 2578706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged remission of tumor-stage mycosis fungoides by topical immunotherpay.
    Vonderheid EC; Dellatorre DL; Van Scott EJ
    Arch Dermatol; 1981 Sep; 117(9):586-9. PubMed ID: 6457569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechlorethamine desensitization in therapy for mycosis fungoides. Topical desensitization to mechlorethamine (nitrogen mustard) contact hypersensitivity.
    Constantine VS; Fuks ZY; Farber EM
    Arch Dermatol; 1975 Apr; 111(4):484-8. PubMed ID: 1122150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Narrowband UVB phototherapy for early-stage mycosis fungoides: evaluation of clinical and histopathological changes.
    Gökdemir G; Barutcuoglu B; Sakiz D; Köşlü A
    J Eur Acad Dermatol Venereol; 2006 Aug; 20(7):804-9. PubMed ID: 16898902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycosis fungoides. Topical use of nitrogen mustard in recurrent cases.
    Arundell FD; Chan WH
    Calif Med; 1968 Dec; 109(6):458-61. PubMed ID: 5724878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A chart review of patients with early stage mycosis fungoides treated with psoralen plus UVA (PUVA).
    Soung J; Muigai W; Amin N; Stern DK; Lebwohl MG
    J Drugs Dermatol; 2005; 4(3):290-4. PubMed ID: 15898283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
    Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
    J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical chemotherapy and immunotherapy of mycosis fungoides: intermediate-term results.
    Vonderheid EC; Van Scott EJ; Johnson WC; Grekin DA; Asbell SO
    Arch Dermatol; 1977 Apr; 113(4):454-62. PubMed ID: 848974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of mycosis fungoides with ointment-based mechlorethamine.
    Price NM; Deneau DG; Hoppe RT
    Arch Dermatol; 1982 Apr; 118(4):234-7. PubMed ID: 7065680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Milia in regressing plaques of mycosis fungoides: provoked by topical nitrogen mustard or not?
    Kalayciyan A; Oguz O; Demirkesen C; Serdaroglu S; Kotogyan A
    Int J Dermatol; 2004 Dec; 43(12):953-6. PubMed ID: 15569030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.